|

Exploring Cortical Remyelination in Children With Multiple Sclerosis

RECRUITINGN/ASponsored by Assistance Publique - Hôpitaux de Paris
Actively Recruiting
PhaseN/A
SponsorAssistance Publique - Hôpitaux de Paris
Started2022-08-11
Est. completion2025-09-11
Eligibility
Age12 Years – 18 Years
Healthy vol.Accepted

Summary

Multiple sclerosis (MS) in children, a rare disease, follows a relapsing remitting course with a shorter interval between the first 2 clinical events and higher annualized relapse rate as compared with MS in adults. Residual deficits following clinical events are less frequent. The vast majority of children and adolescents with MS are thought to have a greater potential for myelin repair than adults. However convincing data in the literature to support this hypothesis are lacking, because until now no imaging technique has been validated to measure remyelination in vivo.

Eligibility

Age: 12 Years – 18 YearsHealthy volunteers accepted
Inclusion Criteria for patients :

* age between 12 years old and 18 years old
* RR-MS defined by 2017 McDonald criteria
* no relapse the last 4 weeks
* no methylprednisolone or prednisolone the last 4 weeks.
* affiliated to the social security system
* signature of the consent by the 2 holders of parental authority

Inclusion Criteria for Volunteers:

* age between 12 years old and 18 years old
* absence of any neurological
* signature of the consent by the 2 holders of parental authority

Exclusion Criteria for both groups:

* Parental rejection
* Contre-indication of brain MRI: pace maker, tatoo of the face, claustrophobia….
* Pregnancy, copper intrauterine device

Conditions2

Children With Multiple SclerosisMultiple Sclerosis

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.